Buchinger H, Grundmann U, Ziegeler S
Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum des Saarlandes, 66421 Homburg/Saar, Germany.
Anaesthesist. 2005 Sep;54(9):861-70. doi: 10.1007/s00101-005-0902-6.
Reduction of the perioperative cardiovascular risk with pharmacological interventions plays a prominent role in routine anesthesia practice. For example, perioperative beta-blockade is well established in anesthesiological treatment of patients. There is a growing body of evidence supporting the cardioprotective effects of volatile anesthetics known as anesthetic-induced preconditioning. There are numerous and complex data from animal studies. The mechanisms of anesthetic-induced preconditioning have been extensively studied but have still not been clearly identified. Initial clinical data show the cardioprotective effects of volatile agents by looking at parameters of myocardial function and laboratory values and therefore, the question of the relevance of these data for routine clinical practice has been raised. This review gives a summary of the currently available data focusing on the mechanisms of anesthesiological preconditioning and clinical studies.
通过药物干预降低围手术期心血管风险在常规麻醉实践中起着重要作用。例如,围手术期β受体阻滞剂在患者的麻醉治疗中已得到广泛应用。越来越多的证据支持挥发性麻醉剂的心脏保护作用,即麻醉诱导的预处理。动物研究中有大量复杂的数据。麻醉诱导预处理的机制已得到广泛研究,但仍未明确。初步临床数据通过观察心肌功能参数和实验室值显示了挥发性药物的心脏保护作用,因此,这些数据与常规临床实践的相关性问题也随之而来。本综述总结了目前关于麻醉预处理机制和临床研究的现有数据。